Graf Akcie ALNY (Alnylam Pharmaceuticals Inc). Diskuze k akciím ALNY. Aktuální informace ALNY.

Základní informace o společnosti Alnylam Pharmaceuticals Inc (Akcie ALNY)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 24.31B
Hodnota podniku (EV) 20.42B
Tržby 687.534M
EBITDA -708.47
Zisk -886.68
Růst v tržbách Q/Q 112.15 %
Růst v tržbách Y/Y 99.18 %
P/E (Cena vůči ziskům) N/A
Forward P/E -0.24
EV/Sales 29.70
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 35.36
P/FCF N/A
Price/Book 23.92
Účetní hodnota na akcii 8.72
Hotovost na akcii 16.08
FCF vůči ceně -2.69 %
Počet zaměstnanců 1,453
Tržba na zaměstnance 473.182k
Profit margin -174.15 %
Operating margin -109.35 %
Gross margin 84.16 %
EBIT margin -110.61 %
EBITDA margin -103.05 %
EPS - Zisk na akcii N/A
EPS - Kvartální růst 3.21 %
EPS - Očekávaný růst příští rok -27.98 %
Return on assets -26.31 %
Return on equity -88.43 %
ROIC -26.58 %
ROCE -25.74 %
Dluhy/Equity 2.35
Čistý dluh/EBITDA 7.32
Current ratio 4.91
Quick Ratio 4.76
Volatilita 2.97
Beta 0.97
RSI 65.38
Cílová cena analytiků 163
Známka akcie (dle analytiků) 1.71
Insider ownership 0.62 %
Institutional ownership 94.70 %
Počet akcií 118.848M
Procento shortovaných akcií 3.92 %
Short ratio 6.90 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 2004
Země United States

Finanční výsledky akcie ALNY

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$492.853$219.75$74.908$89.912$47.159$41.097
Cost Of Goods Sold$78.052$25.062$1.802---
Gross Profit$414.801$194.688$73.106$89.912$47.159$41.097
Research And Development Expenses$654.819$655.114$505.42$390.635$382.392$276.495
SG&A Expenses$588.42$479.005$382.359$199.365$89.354$60.61
Other Operating Income Or Expenses------
Operating Expenses$1,321.291$1,159.181$889.581$590$471.746$337.105
Operating Income$-828.438$-939.431$-814.673$-500.088$-424.587$-296.008
Total Non-Operating Income/Expense$-27.162$54.178$53.999$9.214$14.479$5.935
Pre-Tax Income$-855.6$-885.253$-760.674$-490.874$-410.108$-290.073
Income Taxes$2.681$0.863$0.823---
Income After Taxes$-858.281$-886.116$-761.497$-490.874$-410.108$-290.073
Other Income------
Income From Continuous Operations$-858.281$-886.116$-761.497$-490.874$-410.108$-290.073
Income From Discontinued Operations------
Net Income$-858.281$-886.116$-761.497$-490.874$-410.108$-290.073
EBITDA$-754.003$-885.063$-799.425$-488.19$-409.457$-276.958
EBIT$-828.438$-939.431$-814.673$-500.088$-424.587$-296.008
Basic Shares Outstanding115109101918684
Shares Outstanding115109101918684
Basic EPS$-7.46$-8.11$-7.57$-5.42$-4.79$-3.45
EPS - Earnings Per Share$-7.46$-8.11$-7.57$-5.42$-4.79$-3.45
# 2020 2019 2018 2017 2016 2015
Current Ratio4.46764.86646.689312.23385.101617.8004
Long-term Debt / Capital0.1584-0.02250.01670.1402-
Debt/Equity Ratio0.1882-0.0230.0170.163-
Gross Margin84.163288.595297.5944100100100
Operating Margin-168.0903-427.4999-1087.565-556.1971-900.3308-720.2667
EBIT Margin-168.0903-427.4999-1087.565-556.1971-900.3308-720.2667
EBITDA Margin-152.9874-402.7591-1067.209-542.9642-868.2478-673.913
Pre-Tax Profit Margin-173.6015-402.8455-1015.478-545.9493-869.6282-705.8253
Net Profit Margin-174.1454-403.2383-1016.576-545.9493-869.6282-705.8253
Asset Turnover0.14470.09170.04760.04510.03730.0296
Inventory Turnover Ratio1.03790.44480.0749---
Receiveable Turnover0.81815.10923.9932.64432.0214.9526
Days Sales In Receivables446.138671.440491.4108138.032180.599973.6981
ROE - Return On Equity-84.4559-61.5918-58.4883-27.789-44.5663-22.9359
Return On Tangible Equity-84.4559-61.5918-58.4883-27.789-44.5663-22.9359
ROA - Return On Assets-25.1912-36.9965-48.3551-24.6085-32.4758-20.9211
ROI - Return On Investment-71.0777-61.5918-57.171-27.325-38.3199-22.9359
Book Value Per Share8.728612.823912.868217.723310.707614.8631
Operating Cash Flow Per Share-2.79993.045-1.366-0.6324-1.3429-0.0219
Free Cash Flow Per Share-2.12913.0237-1.4766-1.029-1.9429-0.0554